A Real-World Study of Ipilimumab Treatment After Nivolumab Treatment in Melanoma in Japan

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

NCT01511913 ·Status: COMPLETED

Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma

NCT04099251 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma

NCT01927419 ·Status: COMPLETED ·Phase: PHASE2

Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma

NCT00636168 ·Status: COMPLETED ·Phase: PHASE3

Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED

NCT02523313 ·Status: COMPLETED ·Phase: PHASE2

Observational Study of Nivolumab Monotherapy or in Combination With Ipilimumab in Participants With Advanced Melanoma and in Participants With Adjuvant Nivolumab Therapy

NCT02990611 ·Status: COMPLETED

A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma

NCT01654692 ·Status: COMPLETED ·Phase: PHASE2

Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma

NCT01696045 ·Status: TERMINATED ·Phase: PHASE2

Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)

NCT01783938 ·Status: COMPLETED ·Phase: PHASE2

Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic Melanoma

NCT06566391 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Prospective Non-Interventional Study in Participants Receiving Nivolumab in Adjuvant Setting for Resected Melanoma in Real-World Conditions in France

NCT04550247 ·Status: ACTIVE_NOT_RECRUITING

Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma

NCT02388906 ·Status: COMPLETED ·Phase: PHASE3

An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma

NCT03068455 ·Status: COMPLETED ·Phase: PHASE3

A Study of Treatment Patterns and Outcomes in Participants With Stage IIIA Melanoma Receiving Adjuvant Systemic Therapy

NCT05432622 ·Status: COMPLETED

An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself

NCT02320058 ·Status: COMPLETED ·Phase: PHASE2

Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants

NCT04495010 ·Status: WITHDRAWN ·Phase: PHASE2

Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma

NCT02970981 ·Status: COMPLETED ·Phase: PHASE2

A Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic Melanoma

NCT03153085 ·Status: COMPLETED ·Phase: PHASE2

PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma

NCT01621490 ·Status: COMPLETED ·Phase: PHASE1

A Pilot Study of Ipilumimab and Radiation in Poor Prognosis Melanoma

NCT01996202 ·Status: COMPLETED ·Phase: PHASE1

A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

NCT02714218 ·Status: COMPLETED ·Phase: PHASE3

Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV Melanoma

NCT01676649 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma

NCT03728465 ·Status: TERMINATED ·Phase: PHASE2

Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma

NCT01245556 ·Status: COMPLETED ·Phase: PHASE1

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

NCT01515189 ·Status: COMPLETED ·Phase: PHASE3